Novelties in the multifaceted miconazole effects on skin disorders

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 11, 2008, Pages 1927-1934

  Quatresooz, Pascale ^a   Vroome, Valérie ^b   Borgers, Marcel ^b,c   Cauwenbergh, Geert ^c   Piérard, Gérald E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Barrier Therapeutics   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Azole; Ergosterol; Fungus; Hydrogen peroxide; Miconazole

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CALCINEURIN INHIBITOR; CATALASE; CLOTRIMAZOLE; CYTOCHROME P450; ERGOSTEROL; FARNESOL; FLUCONAZOLE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MICONAZOLE NITRATE; NYSTATIN; PEROXIDASE; PHOSPHOLIPID; PYRROLE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STEROL 14ALPHA DEMETHYLASE; TRIACYLGLYCEROL; TRIAZOLE;

ACNE VULGARIS; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; APPLICATION SITE ERYTHEMA; ATOPIC DERMATITIS; CANDIDA ALBICANS; CANDIDIASIS; CELL DEATH; DERMATOMYCOSIS; DIAPER DERMATITIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; KERATOLYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRURITUS; REVIEW; SKIN BURNING SENSATION; SKIN DISEASE; STEROL SYNTHESIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TINEA VERSICOLOR;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DERMATOMYCOSES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICONAZOLE; SKIN DISEASES, BACTERIAL;

EID: 49649089506     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.11.1927     Document Type: Review

References (49)

1. Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004;5:225-37
2. Borgers M, Degreef H, Cauwenbergh G. Fungal infections of the skin: infection process and antimycotic therapy. Curr Drug Targets 2005;6:849-62
3. Pierard GE, Pierard-Franchimont C, Vroome V, et al. Established and emerging oral antifungals in dermatology. In: Walters Ka, Roberts MS, editors, Dermatological and cosmeceutical development. Publ. Marcel Dekker, New York: USA; In press
4. Van Cutsem JM, Thienpont D. Miconazole a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 1972;17:392-404
5. Fothergill AW. Miconazole: a historical perspective. Expert Rev Antiinfect Ther 2006;4:171-5
6. De Nollin S, Borgers M. An ultrastructural and cytochemical study of Candida albicans after in vitro treatment with imidazoles. Mykosen 1976;19:317-28
7. Heel RC, Brogden RN, Pakes GE, et al. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980;19:7-30
8. Yamaguchi T, Hiratani T, Plempel M. In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole. Arzneim Forsch 1983;33:546-51
9. Odds FC, Abbott AB, Pye G, Troke PF. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol 1986;24:305-11
10. Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev Infect Dis 1980;2:520-34
11. Kelly SL, Lamb DC, Baldwin BC, et al. Characterization of Saccharomyces cerevisiae CYP61, sterol D2-desaturase, and inhibition by azole antifungal agents. J Biol Chem 1997;272:9986-8
12. Degreef H, Heeres J, Borgers M. Antifungal azoles for skin disorders. Expert Opin Ther Patents 2006;16:1235-53
13. Van Den Bossche H, Willemsens G, Cools W, Lauwers WF: Effects of miconazole on the fatty acid pattern in Candida albicans. Arch Int Physiol Biochim 1981;89:B134
14. Francois I, Thevissen K, Meert EM, et al. Involvement of lipid rafts in antifungal mode of action of miconazole [abstr. p 1818]. J Am Acad Dermatol 2007;56
15. De Nollin S, Van Belle H, Goossens F, et al. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chem 1977;11:500-13
16. Kobayashi D, Kondo K, Uehara N, et al. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob Agents Chemother 2002;46:3113-7
17. François IEJ, Cammue BP, Borgers M, et al. Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogeneous reactive oxygen species production in Candida albicans. Anti-infect Agents Med Chem 2006;5:3-13
18. Thevissen K, Ayscough KR, Aerts AM, et al. Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast. J Biol Chem 2007;282:21592-7
19. Borgers M, De Nollin S, Thoné F, Van Belle H. Cytochemical localization of NADH oxidase in Candida albicans. Histochem Cytochem 1977;25:193-9
20. Dumitri R, Hornby JM, Nickerson KW. Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungals drugs. Antimicrob Agents Chemother 2004;48:2350-4
21. Edlind T, Smith L, Henry K, et al. Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbial 2002;46:257-68
22. Onyewu C, Blankenship JR, Del Poetan, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, Candida krusei. Antimicrob Agents Chem 2003;47:956-64
23. Mac Neil S, Dawson RA, Crocker G, et al. Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity. Br J Dermatol 1993;128:143-50
24. Xhauflaire-Uhoda E, Vroome V, Cauwenbergh G, Pierard GE. Dynamics of skin barrier repair following topical applications of miconazole nitrate. Skin Pharmacol Physiol 2006;19:290-4
25. De Nollin S, Borgers M. The ultrastructure of Candida albicans after in vitro treatment with miconazole. Saboraudia 1974;12:341-51
26. Pierard GE, Pierard-Franchimont C, Arrese JE. Comparative study of the activity and lingering effect of topical antifungals. Skin Pharmacol 1993;6:208-14
27. Fulton JE. Micanazole therapy for endemic fungal disease. Arch Dermatol 1975;113:596-8
28. Sawyer PR, Brogden RN, Pinder RM, et al. Miconazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1975;9:406-23
29. Ongley RC. Efficacy of topical miconazole treatment of tinea pedis. Can Med. Assoc J 1978;119:353-4
30. Clayton YM, Gange RW, MacDonald DM, Carruthers JA. A clinical double-blind trial of topical haloprogin and miconazole against superficial fungal infections. Clin Exp Dermatol 1979;4:65-73
31. Tanenbaum L, Anderson C, Rosenberg MJ, Akers W. 1% sulconazole cream v 2% miconazole cream in the treannent of tinea versicolor. Arch Dermatol 1984;120:216-9
32. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988;1:187-217
33. Warshaw EM, St Clair KR. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol 2005;53:717-20
34. Henry F, Pierard-Franchimont C, Flagothier C, Pierard GE. How I treat... a stoutness-associated intertrigo. Rev. Med. Liège 2007;62:67-70
35. Wong AW, Hon EK, Zee B. Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control. Int J Dermatol 2008;47:187-91
36. Pitcher DG, Noble WC, Seville RH. Treatment of erythrasma with miconazole. Clin Exp Dermatol 1979;4:453-6
37. Nolting S, Strauss WB. Treatment of impetigo and ecthyma: a comparison of sulconazole with miconazole. Int J Dermatol 1988;27:716-9
38. Pierard-Franchimont C, Letawe C, Pierard GE. Tribological and mycological consequences of the use of miconazole nitrate-containing paste for the prevention of diaper dermatitis: an open pilot study. Eur J Pediatr 1996;155:756-8
39. Concannon P, Gisoldi E, Phillips S, Grossman R. Diaper dermatitis: a therapeutic dilemma. Results of a double-blind placebo controlled trial of miconazole nitrate 0.25%. Pediatr Dermatol 2001;18:149-55
40. Flagothier C, Pierard-Franchimont C, Pierard GE. How I explore... diaper dermatitis. Rev Med Liège 2004;59:106-9
41. Spraker MK, Gisoldi EM, Siegfried EC, et al. Topical miconazole nitrate ointment in the treatment of diaper dermatitis complication by candidiasis. Cutis 2006;77:113-20
42. Eichenfield LF, Bogen ML, Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis. J Drugs Dermatol 2007;6:522-6
43. Degreef H, Vanden Bussche G. Double blind evaluation of a miconazole-benzoylperoxide combination for topical treatment of acne vulgaris. Dermatologica 1982;164:201-8
44. Reinel D, Beierdorfer H. A new drug combination for the topical tratment of acne. Miconazole 2% + benzoyl peroxide 5% versus benzoyl peroxide 5%: a double-blind study. Z Hautkr 1985;60:648-56
45. Mesquita-Guimaraes J, Ramos S, Tavares MR, Carvalhos MR. A double-blind clinical trial with a lotion containing 5% benzoyl peroxide and 2% miconazole in patients with acne vulgaris. Clin Exp Dermatol 1989;14:357-60
46. Petit L, Pierard-Franchimont C, Uhoda E, et al. Coping with mild inflammatory catamenial acne. A clinical and bioinstrumental split-face assessment. Skin Res Technol 2004;10:278-82
47. Flagothier C, Vroome V, Borgers M, et al. Effect of a single overnight topical application of miconazole nitrate paste on acne papules. Int J Dermatol 2006;45:316-9
48. Xhauflaire-Uhoda E, Pierard GE. Skin capacitance imaging of acne lesions. Skin Res Technol 2007;13:9-12
49. Barillaro V, Dive G, Bertholet P, et al. Theoretical and experimental investigations on miconazole/cyclodextrun/acid complexes: molecular modelling studies. Int J Pharm 2007;342:152-60